A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
Eligible age
1–23 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment for B-cell Acute Lymphoblastic Leukemia/Lymphoma. The main study aims are: * Evaluate the persistence of protective immunity to routine childhood vaccinations in participants with B-ALL/Ly who have received blinatumomab. * To determine whether revaccination in participants with non-protective titers leads to restored humoral immunity. Researchers will compare results from participants who have received immunotherapy to those who have not received immunotherapy to see if immunotherapy versus other chemotherapeutic drugs adversely affect the protective immunity acquired through vaccination.
Sponsor: Arkansas Children's Hospital Research Institute
You may qualify if…
- ✓ Diagnosis of B-lineage acute lymphoblastic leukemia/lymphoma
- ✓ ≥1 year old and up to 21 years old at diagnosis
- ✓ Informed consent provided, and if applicable, child assent provided
- ✓ Must have received all vaccinations routinely administered during first year of life
You may not qualify if…
- ✕ Relapsed/refractory disease at any time
- ✕ Received or will require a bone marrow transplant and/or cellular therapy
- ✕ Pregnancy
Where it's recruiting
Little Rock · Springdale
Source: ClinicalTrials.gov · NCT07422337 · last updated 2026-02-25